Literature DB >> 30825976

MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer.

Roy P J van den Ende1, Lisanne S Rigter2, Ellen M Kerkhof3, Els L van Persijn van Meerten4, Eva C Rijkmans3, Doenja M J Lambregts5, Baukelien van Triest6, Monique E van Leerdam2, Marius Staring7, Corrie A M Marijnen3, Uulke A van der Heide8.   

Abstract

BACKGROUND AND
PURPOSE: A GTV boost is suggested to result in higher complete response rates in rectal cancer patients, which is attractive for organ preservation. Fiducials may offer GTV position verification on (CB)CT, if the fiducial-GTV spatial relationship can be accurately defined on MRI. The study aim was to evaluate the MRI visibility of fiducials inserted in the rectum.
MATERIALS AND METHODS: We tested four fiducial types (two Visicoil types, Cook and Gold Anchor), inserted in five patients each. Four observers identified fiducial locations on two MRI exams per patient in two scenarios: without (scenario A) and with (scenario B) (CB)CT available. A fiducial was defined to be consistently identified if 3 out of 4 observers labeled that fiducial at the same position on MRI. Fiducial visibility was scored on an axial and sagittal T2-TSE sequence and a T1 3D GRE sequence.
RESULTS: Fiducial identification was poor in scenario A for all fiducial types. The Visicoil 0.75 and Gold Anchor were the most consistently identified fiducials in scenario B with 7 out of 9 and 8 out of 11 consistently identified fiducials in the first MRI exam and 2 out of 7 and 5 out of 10 in the second MRI exam, respectively. The consistently identified Visicoil 0.75 and Gold Anchor fiducials were best visible on the T1 3D GRE sequence.
CONCLUSION: The Visicoil 0.75 and Gold Anchor fiducials were the most visible fiducials on MRI as they were most consistently identified. The use of a registered (CB)CT and a T1 3D GRE MRI sequence is recommended.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gold fiducial marker; IGRT; MRI; Rectal cancer

Mesh:

Substances:

Year:  2018        PMID: 30825976     DOI: 10.1016/j.radonc.2018.11.016

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Manual and semi-automated delineation of locally advanced rectal cancer subvolumes with diffusion-weighted MRI.

Authors:  Nathan Hearn; William Bugg; Anthony Chan; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2020-09-02       Impact factor: 3.039

2.  Development of an Orthotopic Murine Model of Rectal Cancer in Conjunction With Targeted Short-Course Radiation Therapy.

Authors:  Taylor P Uccello; Sarah A Kintzel; Bradley N Mills; Joseph D Murphy; Jesse Garrett-Larsen; Nicholas G Battaglia; Carlos J Rodriguez; Michael G Drage; Jian Ye; Tanzy M T Love; Carl J Johnston; Elizabeth A Repasky; Haoming Qiu; David C Linehan; Edith M Lord; Scott A Gerber
Journal:  Adv Radiat Oncol       Date:  2021-12-09

3.  Accurate surgical navigation with real-time tumor tracking in cancer surgery.

Authors:  Jasper Nijkamp; Theo J M Ruers; Esther N D Kok; Roeland Eppenga; Koert F D Kuhlmann; Harald C Groen; Ruben van Veen; Jolanda M van Dieren; Thomas R de Wijkerslooth; Monique van Leerdam; Doenja M J Lambregts; Wouter J Heerink; Nikie J Hoetjes; Oleksandra Ivashchenko; Geerard L Beets; Arend G J Aalbers
Journal:  NPJ Precis Oncol       Date:  2020-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.